Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jérôme Boursier, Philippe Mathurin, Céline Ribet, Victor Ledinghen, Marie Zins, Marie‐Aline Charles – 25 April 2022
Jorge Reyes, Evelyn Hsu – 25 April 2022
Stefano Ciardullo, Marco Carbone, Pietro Invernizzi, Gianluca Perseghin – 25 April 2022 – Recently, an expert panel proposed diagnostic criteria for metabolic dysfunction–associated fatty liver disease (MAFLD) in the pediatric population. The aim of this study was to evaluate the prevalence of MAFLD among US adolescents and to investigate whether the new MAFLD definition is able to identify individuals with more advanced liver disease.
Robert A. Fisher – 25 April 2022
Manhal Izzy, Hilary M. DuBrock – 25 April 2022
AASLD created a variety of resources to help hepatologists and liver patients navigate COVID-19.
This is the first AASLD Practice Guidance on the management of malnutrition, frailty, and sarcopenia in patients with cirrhosis
Hepatocellular Carcinoma (HCC) is now the fifth-most common cancer in the world and the third cause of cancer-related mortality as estimated by the World Health Organization.
AASLD develops evidence-based practice guidelines which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. AASLD also provides practice tools to assist with learning and implementing the new recommendations.
Hepatic encephalopathy (HE) is a frequent complication and one of the most debilitating manifestations of liver disease, severely affecting the lives of patients and their caregivers.